Allergan’s Mixed R&D News Gives It A Shot In The Eye
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan announced plans to initiate a Phase III clinical trial for its macular degeneration candidate DARPin and FDA approval of a new indication for the eye drug Ozurdex, but FDA also declined to approve Semprana for migraine.
You may also be interested in...
Valeant Clears Decks, Ups Offer For Allergan – And Says B&L Offers Good Blueprint For Integration
Valeant touted the successes of the B&L acquisition in an effort to prove an Allergan integration would be just as seamless. The increased offer to Allergan came on the heels of Valeant selling its dermatological fillers business to Nestle for $1.4 billion, a move that paves the way for integrating Allergan’s similar portfolio.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.